Neuraxis Stock Price, News & Analysis

NeurAxis, Inc. (NYSE American: NRXS) is a medical technology company in the surgical and medical instrument manufacturing industry. The company focuses on neuromodulation therapies designed to address chronic and debilitating conditions in children and adults. NeurAxis centers its strategy on advancing science and using evidence-based medicine to support adoption of its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology across the medical, scientific, and patient communities.

The company’s core commercial product is IB-Stim, a non-invasive neuromodulation device based on its PENFS technology. According to NeurAxis, IB-Stim is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD), and FD-related nausea symptoms in patients 8 years and older. Company disclosures describe IB-Stim as a percutaneous electrical nerve field stimulator that gently stimulates cranial nerve bundles in the ear to help regulate pain signaling between the gut and the brain in disorders of gut-brain interaction.

NeurAxis emphasizes the unmet medical need in gastrointestinal conditions, particularly in pediatric and adolescent patients with abdominal pain-related disorders of gut-brain interaction (DGBIs). The company notes that there are no FDA-approved drug therapies for certain pediatric abdominal pain-related conditions and no approved drug therapies for adults for pain with functional dyspepsia, and that off-label prescription drugs are often used despite limited efficacy data and potential safety concerns. Against this backdrop, NeurAxis positions IB-Stim as the only FDA-cleared therapy specifically designed for some of these large and underserved pain-related patient populations.

Beyond its initial pediatric focus, NeurAxis has reported expanded regulatory clearances that broaden the potential patient base. In an 8-K filing and related press releases, the company announced FDA 510(k) clearance for its PENFS technology for the treatment of functional abdominal pain associated with functional dyspepsia and FD-related nausea symptoms in patients aged 8 years and older, including adults. This expanded indication is described as the first FDA clearance or approval for a treatment specifically addressing functional dyspepsia in the adult patient population, and it builds on earlier clearances in adolescents.

NeurAxis also reports that IB-Stim and its PENFS technology have been incorporated into clinical practice guidelines from leading academic societies for the treatment of functional abdominal pain in IBS. Company communications state that its PENFS technology is the only FDA-cleared or approved treatment recommended in certain pediatric guidelines, which NeurAxis views as an important driver for broader insurance coverage and clinical adoption.

On the reimbursement side, NeurAxis highlights progress in establishing a more durable commercial framework for PENFS procedures. The company has announced the assignment and implementation of a Category I Current Procedural Terminology (CPT) code for Percutaneous Electrical Nerve Field Stimulation. According to NeurAxis, this Category I CPT code provides a permanent, nationally recognized coding and billing pathway for PENFS, reflects broad clinical acceptance, and is used by Medicare, Medicaid, and commercial insurers as a basis for coverage and payment determinations. The company links this coding milestone to improved payer alignment, more consistent reporting and reimbursement for providers, and enhanced scalability across health systems.

NeurAxis also reports expanding medical policy coverage for PENFS from commercial insurers and public sector channels. Press releases describe new coverage decisions from major national health insurers, state-level coverage expansions, and a Veterans Affairs Federal Supply Schedule (FSS) contract that lists IB-Stim as a drug-free treatment option for functional abdominal pain in patients 8 years and older. The company views these developments as broadening access to PENFS-based therapies for both pediatric and adult patients and as supporting its commercial momentum.

In addition to IB-Stim, NeurAxis has disclosed regulatory progress on another device. The company reports receiving 510(k) clearance from the FDA for its Rectal Expulsion Device (RED), which it describes as a rectal expulsion device intended to simplify anorectal function testing in adult patients with chronic constipation and to be usable without interrupting clinical workflow. This product extends the company’s presence within gastrointestinal-focused medical technologies beyond neuromodulation for abdominal pain.

NeurAxis has also engaged in licensing and collaboration activities related to neuromodulation. An 8-K filing describes a prior license and collaboration agreement under which the company granted Masimo Corporation an exclusive, fully paid-up, royalty-free license to certain patents and trademarks in a limited field of use connected to the NSS-2 Bridge device, a percutaneous nerve field stimulator indicated for use in the reduction of symptoms of opioid withdrawal. In 2025, NeurAxis and Masimo entered into a termination agreement under which NeurAxis agreed to pay Masimo for products, assets, trademarks, and patents related to the NSS-2 Bridge device, and NeurAxis disclosed that it would no longer receive licensing payments or other revenue from that device.

From a capital markets perspective, NeurAxis has described itself as a growth-stage company and has used at-the-market equity programs and other financings to support its operations and commercialization efforts. In 8-K filings, the company outlines an At The Market Offering Agreement with a sales agent under which it may offer and sell shares of common stock under an effective shelf registration statement. NeurAxis has also disclosed equity financings backed by institutional investors and the adoption of an Employee Stock Purchase Plan intended to give eligible employees an opportunity to acquire company stock at a discount through payroll deductions.

NeurAxis is headquartered in Carmel, Indiana, and operates within the broader manufacturing sector as part of the surgical and medical instrument manufacturing industry. Its public communications consistently emphasize neuromodulation therapies, gastrointestinal indications, FDA clearances, reimbursement infrastructure, and clinical guideline recognition as central elements of its business model and growth strategy.

Business focus and technology

According to company descriptions in press releases and SEC filings, NeurAxis is focused on neuromodulation therapies that target the interaction between the gut and the brain. Its proprietary PENFS technology, delivered through IB-Stim, is designed as a non-surgical, non-drug device that sends gentle electrical impulses to cranial nerve bundles in the ear. The company positions this mechanism as a way to help regulate pain signaling in functional abdominal pain and related gastrointestinal disorders.

NeurAxis reports that additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. While specific pipeline indications beyond those described for IBS, functional dyspepsia, and associated nausea symptoms are not detailed in the provided materials, the company’s disclosures emphasize ongoing research and evidence development to support broader use of PENFS-based therapies.

Regulatory and reimbursement environment

Regulatory status and reimbursement are central to NeurAxis’s narrative. The company’s communications highlight multiple FDA 510(k) clearances for IB-Stim and its expanded indications, as well as the first FDA clearance or approval for treatment specifically addressing functional dyspepsia in adults. NeurAxis also notes that its PENFS technology has been recognized in clinical practice guidelines from academic societies, which it views as an important factor in payer decision-making.

The assignment and implementation of a Category I CPT code for PENFS procedures is described as a major commercial milestone. NeurAxis states that Category I CPT codes are routinely used by Medicare, Medicaid, and commercial insurers to determine coverage and payment, and that having a permanent code provides a consistent framework for providers to report PENFS procedures. The company links this coding status to expanded patient access, reinforcement of its reimbursement model, and greater predictability in its commercial trajectory.

Capital structure and corporate actions

NeurAxis’s SEC filings describe several corporate and financing actions. These include an at-the-market equity offering program under a shelf registration statement on Form S-3, adjustments to the maximum aggregate offering amount under that program, and equity financings supported by institutional investors. The company has also adopted an Employee Stock Purchase Plan that allows eligible employees to purchase common stock at a discount, subject to share limits and potential annual increases.

In addition, NeurAxis has managed its intellectual property and collaboration arrangements through licensing and termination agreements, as illustrated by its prior relationship with Masimo related to the NSS-2 Bridge device. The termination of that agreement, and the associated payments and transfer of assets, trademarks, and patents, are part of the company’s disclosed efforts to refine its portfolio and revenue sources.

FAQs about NeurAxis, Inc. (NRXS)

• What does NeurAxis, Inc. do?
  NeurAxis, Inc. is a medical technology company that develops and commercializes neuromodulation therapies for chronic and debilitating conditions in children and adults. Its primary focus is on gastrointestinal-related pain conditions using its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology.
• What is IB-Stim?
  IB-Stim is NeurAxis’s proprietary PENFS-based device. Company disclosures describe it as a non-invasive neuromodulation device that gently stimulates cranial nerve bundles in the ear to help regulate pain signaling between the gut and the brain. IB-Stim is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia, and related nausea symptoms in patients 8 years and older.
• Which conditions does NeurAxis target with its therapies?
  According to NeurAxis, its PENFS technology and IB-Stim are used for functional abdominal pain associated with IBS, functional dyspepsia, and FD-related nausea symptoms. The company also notes that additional clinical trials of PENFS are underway in multiple pediatric and adult conditions with large unmet healthcare needs.
• How is NeurAxis’s PENFS therapy reimbursed?
  NeurAxis reports that Percutaneous Electrical Nerve Field Stimulation procedures have an assigned Category I CPT code, which provides a permanent, nationally recognized coding and billing pathway. The company states that this code is used by Medicare, Medicaid, and commercial insurers as a basis for coverage and payment determinations and supports more consistent reporting and reimbursement for providers.
• What makes IB-Stim distinct in the treatment landscape?
  Company communications emphasize that IB-Stim is the only FDA-cleared therapy specifically designed for certain pediatric abdominal pain-related disorders of gut-brain interaction and that its PENFS technology is the only FDA-cleared or approved treatment recommended in specific pediatric clinical practice guidelines for functional abdominal pain in IBS. NeurAxis also highlights the absence of FDA-approved drug therapies for some pediatric and adult functional dyspepsia-related pain indications.
• What is the Rectal Expulsion Device (RED)?
  NeurAxis has disclosed that it received 510(k) clearance from the FDA for its Rectal Expulsion Device (RED). The company describes RED as a device that simplifies anorectal function testing in adult patients with chronic constipation and can be used without interrupting clinical workflow.
• Has NeurAxis entered into licensing or collaboration agreements?
  Yes. An 8-K filing describes a prior license and collaboration agreement with Masimo Corporation related to the NSS-2 Bridge device, a percutaneous nerve field stimulator indicated for reduction of opioid withdrawal symptoms. NeurAxis later entered into a termination agreement under which it agreed to pay Masimo for products, assets, trademarks, and patents related to the device, and NeurAxis disclosed that it would no longer receive licensing revenue from NSS-2 Bridge.
• How does NeurAxis raise capital?
  NeurAxis’s SEC filings describe the use of an at-the-market equity offering program under a shelf registration statement on Form S-3, as well as equity financings with institutional investors. The company has also adopted an Employee Stock Purchase Plan that allows eligible employees to buy company stock at a discount, subject to plan limits.
• Where is NeurAxis headquartered and what is its industry classification?
  NeurAxis is headquartered in Carmel, Indiana, and is classified in the manufacturing sector within the surgical and medical instrument manufacturing industry.
• Is NeurAxis focused only on pediatric patients?
  While NeurAxis initially emphasized pediatric and adolescent patients, the company reports FDA 510(k) clearance for its PENFS technology for functional abdominal pain associated with functional dyspepsia and FD-related nausea symptoms in patients aged 8 years and older, including adults. It also notes that there are no FDA-approved drug therapies for adults for pain with functional dyspepsia, underscoring its interest in both pediatric and adult markets.